2016-11-14T10:49:28-06:00 2015-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1700 BELLEVUE WA 98004 990 2015-01-01 911608978 INFECTIOUS DISEASE RESEARCH INSTITUTE INFE 2063810883 1616 EASTLAKE AVE E NO 400 SEATTLE WA 98102 C STEPHEN CORDIAL CFO 2063810883 2016-11-09 1 JANE M SEARING P00000565 4254544919 2016-11-09 2015 2017-02-10 21:41:12Z C STEPHEN CORDIAL 1616 EASTLAKE AVE E NO 400 SEATTLE WA 98102 30092807 0 X WWW.IDRI.ORG X 1993 WA DEVELOP VACCINES, DIAGNOSTICS & DRUGS TO PREVENT, DETECT & TREAT INFECTIOUS DISEASES OF POVERTY. 10 8 163 8 429875 -383844 9413720 19664811 4038190 6098639 -6326 857163 719744 1678789 14165328 28299402 9000 14000 0 0 10726682 10818103 958 0 205491 13598667 14273737 24335307 25105840 -10169979 3193562 36163621 37205100 19849406 21319603 16314215 15885497 X AS A "NONPROFIT BIOTECH," IDRI COMBINES THE HIGH-QUALITY SCIENCE OF A RESEARCH ORGANIZATION WITH THE PRODUCT DEVELOPMENT CAPABILITIES OF A BIOTECH COMPANY TO CREATE NEW DIAGNOSTICS, DRUGS AND VACCINES FOR INFECTIOUS DISEASES AND IMPROVE THE HEALTH OF THE WORLD. 0 0 7528217 1632502 VACCINE RESEARCH - ONE OF THE GREATEST TRIUMPHS OF PUBLIC HEALTH, VACCINES HAVE BEEN USED FOR DECADES TO BOOST IMMUNITY AND PROTECT AGAINST SERIOUS DISEASES. IDRI SCIENTISTS ARE DEVELOPING INNOVATIVE VACCINES AGAINST DEADLY INFECTIOUS DISEASES SUCH AS TUBERCULOSIS, LEISHMANIASIS, AND LEPROSY, AS WELL AS NEWLY EMERGING THREATS INCLUDING ZIKA AND CHIKUNGUNYA. THE GOAL OF IDRI'S VACCINE WORK IS TO PRODUCE SAFE, EFFECTIVE AND LOW-COST VACCINES AND TO TRANSFER VACCINE TECHNOLOGY AND EXPERTISE TO DEVELOPING COUNTRIES SO THAT VACCINES CAN BE DEVELOPED QUICKLY WHEN DISEASE OUTBREAKS OCCUR. IDRI'S LEADING TUBERCULOSIS VACCINE CANDIDATE (ID93 + GLA-SE) HAS MOVED SUCCESSFULLY THROUGH EARLY STAGE CLINICAL TRIALS IN THE U.S. AND SOUTH AFRICA AND IN IS NOW IN A PHASE 2A CLINICAL TRIAL IN SOUTH AFRICA TO ASSESS THE ABILITY TO REDUCE TB RECURRENCE AFTER TREATMENT. 3478259 754264 ADJUVANT RESEARCH - ADJUVANTS ARE SUBSTANCES ADDED TO VACCINES THAT ENHANCE THE ABILITY OF ANTIGENS TO STIMULATE THE BODY'S IMMUNE RESPONSE. THEY PROVIDE A KEY BENEFIT TO VACCINE DEVELOPMENT BY: IMPROVING IMMUNE RESPONSE, BROADENING VACCINE PROTECTION AND REDUCING THE AMOUNT OF VACCINE NEEDED.IDRI IS A WORLD LEADER IN ADJUVANT DEVELOPMENT AND HAS DEVELOPED MULTIPLE ADJUVANT FORMULATIONS. IN ADDITION TO VACCINES THAT IDRI IS DEVELOPING FOR TUBERCULOSIS, LEPROSY AND LEISHMANIASIS, IDRI SCIENTISTS ARE ALSO WORKING WITH COLLABORATORS TO PROVIDE ADJUVANTS FOR VACCINES BEING DEVELOPED IN VARIOUS DISEASE AREAS, INCLUDING MALARIA, HIV/AIDS, ZIKA AND PANDEMIC FLU. IN ADDITION, IDRI HAS TRANSFERRED ITS ADJUVANT TECHNOLOGIES TO ROMANIA, BRAZIL, SOUTH AFRICA AND INDIA, WHERE IDRI SCIENTISTS TEACH SCIENTISTS AND ENGINEERS HOW TO MANUFACTURE ADJUVANTS FOR THEIR OWN VACCINES. 3847855 834412 TUBERCULOSIS DRUG DISCOVERY - IDRI'S TUBERCULOSIS DRUG DISCOVERY GROUP IS FOCUSED ON DISCOVERING AND DEVELOPING NOVEL DRUGS THAT ARE EFFECTIVE AT CURING DRUG SENSITIVE AND DRUG RESISTANT TB WITH THE ADDED GOAL OF SHORTENING THE TIME IT TAKES TO CURE DISEASE. TO DATE, SCIENTISTS AT IDRI HAVE SCREENED MORE THAN HALF A MILLION COMPOUNDS, CONTINUING THE IDENTIFICATION OF NEW LEADS AND DRUG TARGETS TO COMBAT TB.IDRI IS A FOUNDING MEMBER OF THE LILLY TB DRUG DISCOVERY INITIATIVE - HEADQUARTERED AT IDRI - AND THE TB DRUG ACCELERATOR (TBDA). THE LILLY INITIATIVE IS A UNIQUE PUBLIC-PRIVATE PARTNERSHIP WITH ELI LILLY AND COMPANY AND THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), PART OF THE NATIONAL INSTITUTES OF HEALTH (NIH), WITH A FOCUS ON THE DISCOVERY OF NEW ANTI-TUBERCULOSIS DRUGS. THE TBDA WAS FOUNDED AS A PARTNERSHIP OF SEVEN PHARMACEUTICAL COMPANIES AND FIVE OTHER ORGANIZATIONS, FUNDED IN PART BY THE BILL & MELINDA GATES FOUNDATION, TO TARGET THE DISCOVERY OF NEW TB DRUGS BY COLLABORATING ON EARLY-STAGE DRUG DISCOVERY FOR TUBERCULOSIS. 796915 172812 MANUFACTURING - ONCE A VACCINE CANDIDATE HAS BEEN IDENTIFIED IN THE RESEARCH LAB, THE NEXT CHALLENGE IS TO APPLY THAT DISCOVERY TO THE CLINICAL SETTING. A NECESSARY PART OF THIS TRANSITION IS TO PRODUCE VACCINES UNDER CONTROLLED CONDITIONS SO THAT THEY ARE SUITABLE FOR USE IN HUMAN STUDIES. IDRI HAS DEVELOPED THE TYPE OF MANUFACTURING CAPABILITY REQUIRED TO MOVE A VACCINE FROM LATE STAGE RESEARCH TO EARLY CLINICAL STUDIES. 3054074 14000 2704649 OTHER ACTIVITIES - IDRI'S CLINICAL GROUP DESIGNS AND CONDUCTS EARLY STAGE CLINICAL TRIALS TO TEST THE VACCINE CANDIDATES IDENTIFIED BY IDRI SCIENTISTS OR COLLABORATORS. THROUGH OUR NETWORK OF GLOBAL CONNECTIONS, THE CLINICAL TEAM IS ABLE TO LAUNCH CLINICAL TRIALS ALMOST ANYWHERE IN THE WORLD. 3850989 14000 2877461 18705320 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 34 0 1 163 1 1 1 1 SF 0 0 0 0 0 0 0 0 X 10 8 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 X X C STEPHEN CORDIAL 2063810883 1616 EASTLAKE AVE E SUITE 400 SEATTLE WA 98102 BRUCE CARTER PHD CHAIRMAN 5.00 X X 0 0 0 DAVID PERRY TREASURER 5.00 X X 0 0 0 ERIK IVERSON JD LLM PRES., BUSINESS & OPS, SECRETARY 40.00 X X 284942 0 25904 GAIL CASSELL PHD DIRECTOR 5.00 X 0 0 0 MICHEL DEWILDE PHD DIRECTOR 5.00 X 0 0 0 CHRIS HENTSCHEL PHD DIRECTOR 5.00 X 0 0 0 FRANKLYN PRENDERGAST MD PHD DIRECTOR 5.00 X 0 0 0 MASSIMO RADAELLI PHD DIRECTOR 5.00 X 0 0 0 STEVEN REED PHD PRESIDENT & CSO/DIRECTOR 40.00 X X 302134 0 23157 STEVE CORDIAL DIRECTOR 5.00 X 0 0 0 ROBERT LIN VP, FINANCE 40.00 X 126159 0 6905 ANNA MARIE BECKMANN PHD VP, DEVELOPMENT & REGULATORY 40.00 X 185988 0 24295 TANYA PARISH PHD VP, DRUG DISCOVERY 40.00 X 161860 0 5992 WINSTON WICOMB PHD LATG DIRECTOR, VIVARIUM 40.00 X 156409 0 17059 KIM CLARY DIRECTOR, IP 40.00 X 143715 0 22754 JOSHUA ODINGO PHD DIRECTOR, CHEMISTRY 40.00 X 142045 0 21234 1503252 0 147300 20 0 1 0 XENOMETRICS LLC 2430 NEW HOLLAND PIKE SUITE 300 LANCASTER PA 17601 RESEARCH 147659 CEBU LEPROSY & TB RESEARCH FOUNDATION PO BOX 727 CEBU RP 6000-6053 RESEARCH 131479 CYPROTEX US LLC 313 PLEASANT STREET WATERTOWN MA 02472 RESEARCH 125434 APPLIED STRATEGIES 951 MARINERS ISLAND BLVD SUITE 400 SAN MATEO CA 94404 RESEARCH 125000 DFNET RESEARCH INC 140 LAKESIDE AVENUE SUITE 310 SEATTLE WA 98122 RESEARCH 110426 6 10053571 9611240 19664811 LICENSING 541700 2851050 2851050 SPONSORED RESEARCH 541700 1612495 1612495 SERVICES AND CONTRACTS 541700 1205219 1205219 VIVARIUM INCOME 541700 429875 429875 6098639 5521 5521 1667416 1667416 2645047 1793405 851642 851642 851642 CURRENCY EXCHANGE 561499 11373 11373 11373 28299402 5668764 429875 2535952 14000 14000 769201 298833 428376 41992 7991191 6041091 1832353 117747 221876 167642 52611 1623 1228721 897272 319606 11843 607114 437729 162707 6678 405655 209224 196431 71597 71597 429273 270372 156922 1979 1834 1459 375 148692 41663 107622 -593 163402 27205 136197 1196118 1196118 2717080 2104519 590117 22444 330073 281092 48967 14 48833 15340 33493 1557658 1353083 204575 104519 15470 89049 LAB SUPPLIES 3472109 3310160 161949 SUBCONTRACTS 1626164 1622498 3666 CONTRACTED SERVICES 1152376 1114891 37485 REPAIRS & MAINTENANCE 427135 276242 150893 421219 206994 212836 1389 25105840 18705320 6195029 205491 1338775 4140713 5198288 4571109 12720073 11327238 642237 1582284 56514 183091 24187905 8995035 15015611 15192870 1145047 95159 45433 112636 1643 0 36163621 37205100 1726256 2767026 464869 1715092 17658281 16837485 19849406 21319603 X -857454 1213376 17171669 14672121 16314215 15885497 36163621 37205100 X 3193562 -1031492 -2590788 X 0 1 X 1 1 1 X 14410786 20127852 11743860 9413720 19664811 75361029 14410786 20127852 11743860 9413720 19664811 75361029 23087758 52273271 1157313 896761 683996 727807 1672937 5138814 127472 127472 13705 500 11373 25578 80652893 14630546 0.64810 0.62560 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2013 AMOUNT: $ 500. REIMBURSEMENTS - 2011 AMOUNT: $ 12,502. REFUNDS - 2011 AMOUNT: $ 1,203. CURRENCY EXCHANGE - 2015 AMOUNT: $ 11,373. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 15203205 2787254 12415951 7481189 6207781 1273408 1503511 1503511 15192870 DEFERRED RENT 16837485 16837485 23346504 -1031492 -3921406 -4952898 28299402 0 28299402 24185782 276060 276060 23909722 1196118 1196118 25105840 PART XI, LINE 2D - OTHER ADJUSTMENTS: ROYALTY EXPENSES INCLUDED IN INCOME ON FINANCIAL STATEMENTS PRIOR YEAR PLEDGE ADJUSTMENT INCLUDED IN INCOME ON FINANCIAL STATEMENTS RELATED ORGANIZATION REVENUES INCLUDED IN AUDITED FINANCIAL STATEMENTS FINANCIAL STATEMENT ELIMINATIONS PART XII, LINE 2D - OTHER ADJUSTMENTS: RELATED ORGANIZATION EXPENSES INCLUDED IN AUDITED FINANCIAL STATEMENTS FINANCIAL STATEMENT ELIMINATIONS PART XII, LINE 4B - OTHER ADJUSTMENTS: ROYALTY EXPENSES INCLUDED IN INCOME ON FINANCAL STATEMENTS SOUTH ASIA 0 0 PROGRAM SERVICES RESEARCH 518454 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES RESEARCH 221029 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES RESEARCH 220161 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES RESEARCH 135105 NORTH AMERICA 0 0 PROGRAM SERVICES RESEARCH 12926 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES RESEARCH 865 SUB-SAHARAN AFRICA 0 0 PROGRAM RELATED INVESTMENT PROGRAM RELATED INVESTMENT 112636 SUB-SAHARAN AFRICA PROGRAM SERVICES RESEARCH 0 0 0 0 0 0 1221176 0 1221176 0 0 1 0 0 0 PART I, LINE 3: THE EXPENDITURES REPORTED ON SCHEDULE F, PART I, LINE 3 ARE ON ACCRUAL BASIS OF ACCOUNTING. 1 WHITMAN COLLEGE 345 BOYER AVENUE WALLA WALLA WA 99362 910567740 501(C)(3) 9000 N/A N/A GENERAL SUPPORT 1 0 PART I, LINE 2: ALL PAYMENTS MADE FOR PROGRAM SERVICES WITHIN THE U.S. ARE BASED ON LEGAL AGREEMENTS BETWEEN IDRI AND THE PARTY RECEIVING PAYMENT. THESE AGREEMENTS INCLUDE REQUIREMENTS FOR BOTH PROGRESS AND FINANCIAL REPORTING BASED ON TIME PERIODS OR MILESTONE ACHIEVEMENTS. REPORTS ARE REVIEWED BY SCIENTIFIC AND ADMINISTRATIVE STAFF TO ENSURE THAT THE GOALS OF THE AGREEMENT AND ANY SPECIFIC FINANCIAL RESTRICTIONS ARE BEING MET BEFORE FURTHER PAYMENT IS MADE. MOST AGREEMENTS ALSO CONTAIN A CLAUSE GIVING IDRI THE RIGHT TO AUDIT FINANCIAL RECORDS OF THE PARTY IF NEEDED. X X X 0 0 0 0 0 0 0 0 0 ERIK IVERSON JD LLM PRES., BUSINESS & OPS, SECRETARY 284942 0 0 0 0 0 7950 0 17954 0 310846 0 0 0 STEVEN REED PHD PRESIDENT & CSO/DIRECTOR 302134 0 0 0 0 0 7950 0 15207 0 325291 0 0 0 ANNA MARIE BECKMANN PHD VP, DEVELOPMENT & REGULATORY 185988 0 0 0 0 0 6933 0 17362 0 210283 0 0 0 TANYA PARISH PHD VP, DRUG DISCOVERY 161860 0 0 0 0 0 5992 0 0 0 167852 0 0 0 WINSTON WICOMB PHD LATG DIRECTOR, VIVARIUM 156409 0 0 0 0 0 5851 0 11208 0 173468 0 0 0 KIM CLARY DIRECTOR, IP 143715 0 0 0 0 0 5392 0 17362 0 166469 0 0 0 JOSHUA ODINGO PHD DIRECTOR, CHEMISTRY 142045 0 0 0 0 0 3872 0 17362 0 163279 0 0 0 FORM 990, PART 1, LINE 6: THERE WERE EIGHT VOLUNTEER BOARD MEMBERS DURING THE YEAR. BOARD MEMBERS PARTICIPATE IN STRATEGIC PLANNING, EXECUTIVE LEADERSHIP RECRUITMENT AND SELECTION, INTELLECTUAL PROPERTY STRATEGY, AND IDENTIFICATION OF INSTITUTIONAL LIABILITY. THEY COME FROM A VARIETY OF BACKGROUNDS AND DEMONSTRATE FINANCIAL EXPERTISE, REAL ESTATE LEASING/PURCHASING EXPERTISE, BIO-MEDICAL NOT-FOR-PROFIT EXPERTISE, AND AN UNDERSTANDING OF BUSINESS AND BIOTECH LICENSING. FORM 990, PART VI, SECTION A, LINE 1 STEVEN REED, PRESIDENT & CSO, AND ERIK IVERSON, PRESIDENT OF BUSINESS & OPERATIONS, ARE VOTING BOARD MEMBERS. THEY ARE ALSO COMPENSATED BY THE ORGANIZATION FOR THEIR POSITIONS AS PRESIDENT & CSO AND PRESIDENT OF BUSINESS & OPERATIONS, RESPECTIVELY. THEREFORE, THEY ARE NOT INDEPENDENT VOTING BOARD MEMBERS. FORM 990, PART VI, SECTION B, LINE 11 A DRAFT COPY OF THE FORM 990 AND FORM 990-T IS PRESENTED TO THE AUDIT COMMITTEE FOR REVIEW. THE AUDIT COMMITTEE REVIEWS AND APPROVES THE FORM 990 AND 990-T ON BEHALF OF THE IDRI BOARD OF DIRECTORS. ALL BOARD MEMBERS RECEIVE A COPY OF THE FORM 990 AND 990-T PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C EACH JANUARY, MEMBERS OF THE BOARD OF DIRECTORS AND SENIOR MANAGEMENT ARE GIVEN A COPY OF THE CONFLICT OF INTEREST POLICY. THEY ARE REQUIRED TO FILL IT OUT AND RETURN IT BY THE FIRST BOARD MEETING - USUALLY SOMETIME IN THE FIRST QUARTER. THE SENIOR VICE PRESIDENT OF OPERATIONS AND GENERAL COUNSEL REVIEWS THE QUESTIONNAIRES AND SUMMARIZES THE RESULTS. THE RESULTS ARE COMMUNICATED TO THE BOARD OF DIRECTORS. TO THE EXTENT THAT THERE ARE ANY CONFLICTS, THE MEMBER IS RECUSED FROM ANY DECISION MAKING THAT WOULD INCLUDE THE CONFLICT. WHEN THE OCCASION ARISES, THOSE MEMBERS ALSO REMIND THE GROUP (MANAGEMENT TEAM OR BOARD) THAT THERE IS A POTENTIAL CONFLICT WHEN SPECIFIC DISCUSSION TOPICS ARISE. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE CONDUCTED A FULL CEO PERFORMANCE AND COMPENSATION REVIEW, INITIATED IN MAY 2014, USING AN OUTSIDE INDEPENDENT CONSULTANT. THE REPORT IS IN THE BOARD MATERIALS AND IN THE PERSONNEL FILE. THE DECISIONS ARE IN THE COMPENSATION COMMITTEE NOTES. COMPARATIVE COMPENSATION INFORMATION WAS USED FROM THE CULPEPPER AND RADFORD PROFESSIONAL COMPENSATION FIRMS. THE BOARD CHAIR ALSO DOES AN ANNUAL REVIEW OF ALL OTHER OFFICERS AND KEY EMPLOYEES AND WORKS WITH THE HUMAN RESOURCES DEPARTMENT TO DETERMINE IF THE COMPENSATION IS ADEQUATE. IF AN ADJUSTMENT IS DEEMED NECESSARY, THE BOARD CHAIR CONVENES THE COMPENSATION COMMITTEE AND THE ADJUSTMENT IS ADDRESSED. THE BOARD CHAIR REPORTS BACK TO THE HUMAN RESOURCES DEPARTMENT WHO FOLLOWS THROUGH WITH THE COMMITTEE'S RECOMMENDATION. FORM 990, PART VI, SECTION C, LINE 19 THE IDRI AUDITED FINANCIAL STATEMENTS ARE AVAILABLE ON OUR WEBSITE, WWW.IDRI.ORG. REQUESTS FOR OTHER INFORMATION SUCH AS GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE HANDLED THROUGH OUR FINANCE DEPARTMENT AND INFORMATION IS DISTRIBUTED AS REQUESTED UNLESS CONFIDENTIAL IN NATURE. FORM 990, PART XI, LINE 9: PLEDGE ADJUSTMENT -2,590,788. AFRIGEN BIOLOGICS (PTY) LTD 37 STRAND STREET CAPE TOWN WESTERN CAPE SF 8001 RESEARCH SF INFECTIOUS DISEASE RESEARCH INSTITUTE C -221207 141731 0.51000 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 AFRIGEN BIOLOGICS (PTY) LTD O 115551 COST AFRIGEN BIOLOGICS (PTY) LTD Q 5475 COST AFRIGEN BIOLOGICS (PTY) LTD D 136546 PER AGREEMENT